Investors & Media
Reports
- All
-
- All
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- All
-
- All
- Quarterly Report
- Semiannual report
- Annual Report
-
Ryvu Therapeutics Q3 2024 Financial Report
07/11/20242024
Quarterly Report
-
Ryvu Therapeutics H1 2024 Financial Report
11/09/20242024
Semiannual report
-
Ryvu Therapeutics S.A. Q1 2024 Financial Report
15/05/20242024
Quarterly Report
-
Ryvu Therapeutics S.A. Annual Report 2023
13/03/20242023
Annual Report
Statement of the Supervisory Board of Ryvu Therapeutics S.A. - Management Board's report on the operations and financial statements for 2023
-
Ryvu Therapeutics Q3 2023 Financial Report
29/11/20232023
-
Ryvu Therapeutics H1 2023 Financial Report
13/09/20232023
Semiannual report
-
Ryvu Therapeutics S.A. Q1 2023 Financial Report
16/05/20232023
Quarterly Report
-
Ryvu Therapeutics S.A. Annual Report 2022
24/03/20232022
Annual Report
Statement of the Supervisory Board of Ryvu Therapeutics S.A. - Management Board's report on the operations and financial statements for 2022
-
Ryvu Therapeutics S.A. Q3 2022 Financial Report
23/11/20222022
-
Ryvu Therapeutics H1 2022 Financial Report
29/09/20222022
-
Ryvu Therapeutics S.A. Q1 2022 Financial Report
18/05/20222022
Quarterly Report
-
Ryvu Therapeutics S.A. Annual Report 2021
15/03/20222021
Statement of the Supervisory Board of Ryvu Therapeutics S.A. - Management Board's report on the operations and financial statements for 2021
-
Ryvu Therapeutics S.A. Q3 2021 Financial Report
10/11/20212021
-
Ryvu Therapeutics H1 2021 Financial Report
08/09/20212021
-
Ryvu Therapeutics S.A. Q1 2021 Financial Report
12/05/20212021
-
Ryvu Therapeutics S.A. Annual Report 2020
16/03/20212021
Annual Report
Statement of the Supervisory Board of Ryvu Therapeutics S.A. - Management Board's report on the operations and financial statement for 2020
-
Ryvu Therapeutics S.A. Q3 2020 Financial Report
19/11/20202020
-
Ryvu Therapeutics 2020 H1 Financial Report
15/09/20202020
Semiannual report
-
Ryvu Therapeutics S.A. Q1 2020 Financial Report
10/06/20202020
Quarterly Report
-
Ryvu Therapeutics S.A. Annual Report (Summary) 2019
09/04/20202020
Annual Report
Statement of the Supervisory Board of Ryvu Therapeutics S.A. - functioning of the Audit Committee and the Auditor
-
Raport ESPI QSr 03/2019
06/11/20192019
Quarterly Report
Consolidated Quarterly Report Ryvu Therapeutics 2019 Q3 (Summary)
-
Report ESPI PSr 2019
05/09/20192019
Semiannual report
Consolidated Semiannual Report Selvita Group 2019 H1 (Summary)
-
Report ESPI QSr 01/2019
22/05/20192019
Quarterly Report
Consolidated Quarterly Report Selvita Group 2019 Q1 (Summary)
-
Report ESPI QSr 03/2018
13/11/20182018
Quarterly Report
Consolidated Quarterly Report Selvita Group 2018 Q3 (Summary)
-
Report ESPI – SA-R 2018
21/09/20182018
Annual Report
Selvita Group Annual Report 2018 (Summary)
-
Report ESPI PSr 2018
28/08/20182018
Semiannual report
Consolidated Semiannual Report Selvita Group 2018 H1 (Summary)
-
Report ESPI QSr 01/2018
21/05/20182018
Quarterly Report
Consolidated Quarterly Report Selvita Group 2018 Q1 (Summary)
-
Report ESPI QSr 03/2017
15/11/20172017
Quarterly Report
Consolidated Quarterly Report Selvita Group 2017 Q3 (Summary)
-
Report ESPI – SA-R 2017
21/09/20172017
Annual Report
Selvita Group Annual Report 2017 (Summary)
-
Report ESPI PSr 2017
11/09/20172017
Semiannual report
Consolidated Semiannual Report Selvita Group 2017 H1 (Summary)
-
Report ESPI QSr 01/2017
30/05/20172017
Quarterly Report
Consolidated Quarterly Report Selvita Group 2017 Q1 (Summary)
-
Report ESPI QSr 03/2016
09/11/20162016
Quarterly Report
Consolidated Quarterly Report Selvita Group 2016 Q3 (Summary)
-
Report ESPI – SA-R 2016
21/09/20162016
Annual Report
Selvita Group Annual Report 2016 (Summary)
-
Report ESPI PSr 2016
30/08/20162016
Semiannual report
Consolidated Semiannual Report Selvita Group 2016 H1 (Summary)
-
Report ESPI QSr 01/2016
12/05/20162016
Quarterly Report
Consolidated Quarterly Report Selvita Group 2016 Q1 (Summary)
-
Report ESPI QSr 03/2015
05/11/20152015
Quarterly Report
Consolidated Quarterly Report Selvita Group 2015 Q3 (Summary)
-
Report ESPI – SA-R 2015
21/09/20152015
Annual Report
Selvita Group Annual Report 2015 (Summary)
-
Report ESPI PSr 2015
13/08/20152015
Semiannual report
Consolidated Semiannual Report Selvita Group 2015 H1 (Summary)
-
Report ESPI QSr 01/2015
12/05/20152015
Quarterly Report
Consolidated Quarterly Report Selvita Group 2015 Q1 (Summary)
-
Report EBI 30/2014
06/11/20142014
Quarterly Report
Consolidated Quarterly Report Selvita Group 2014 Q3
-
Report ESPI – SA-R 2014
21/09/20142014
Annual Report
Selvita Group Annual Report 2014 (Summary)
-
Report EBI 27/2014
07/08/20142014
Quarterly Report
Consolidated Quarterly Report Selvita Group 2014 Q2
-
Report EBI 15/2014
13/05/20142014
Quarterly Report
Consolidated Quarterly Report Selvita Group 2014 Q1
-
Report EBI 07/2014
01/02/20142013
Quarterly Report
Consolidated Quarterly Report Selvita Group 2013 Q4
-
Report EBI 28/2013
01/11/20132013
Quarterly Report
Consolidated Quarterly Report Selvita Group 2013 Q3
- All
-
- All
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
-
Current Report ESPI 38/2024
12/12/2024Clinical update on RVU120 Phase II program
2024
-
Current Report ESPI 37/2024
05/12/2024Dosing of the first patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)
2024
-
Current Report ESPI 36/2024
02/12/2024Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
2024
-
Current Report ESPI 35/2024
02/12/2024Recommendation of Ryvu’s project for funding by the Małopolska Centre for Entrepreneurship
2024
-
Current Report ESPI 34/2024
19/11/2024Publication dates for periodic reports in 2025
2024
-
Current Report ESPI 33/2024
19/11/2024Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
2024
-
Current Report ESPI 32/2024
23/10/2024Clinical and preclinical data on RVU120, RVU305, WRN and synthetic lethality platform presented at the 2024 EORTC-NCI-AACR Symposium
2024
-
Current Report ESPI 31/2024
22/10/2024Conclusion of an agreement in the area of operational execution of MEN1703 (SEL24) Phase II clinical trial in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
2024
-
Current Report ESPI 30/2024
09/10/2024Clinical and preclinical data on RVU120, RVU305, WRN and synthetic lethality platform to be presented at the 2024 EORTC-NCI-AACR Symposium
2024
-
Current Report ESPI 29/2024
19/09/2024Dosing of the first patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
2024
-
Current Report ESPI 28/2024
11/09/2024Continuation of the development of PRMT5 program
2024
-
Current Report ESPI 27/2024
29/08/2024Fulfillment of conditions for the disbursement of the Tranche C of financing from the European Investment Bank
2024
-
Current Report ESPI 26/2024
27/06/2024Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 27th, 2024
2024
-
Current Report ESPI 25/2024
27/06/2024Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
2024
-
Current Report ESPI 24/2024
19/06/2024Fulfillment of conditions for the disbursement of the Tranche B of financing from the European Investment Bank
2024
-
Current Report ESPI 23/2024
14/06/2024Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
2024
-
Current Report ESPI 22/2024
14/06/2024Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
2024
-
Current Report ESPI 21/2024
04/06/2024Conclusion of funding agreement with the Polish Agency for Enterprise Development
2024
-
Current Report ESPI 20/2024
29/05/2024Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
2024
-
Current Report ESPI 19/2024
29/05/2024Obtaining the status of Associate Partner within IPCEI Med4Cure
2024
-
Current Report ESPI 18/2024
28/05/2024Conclusion of funding agreement with the National Centre for Research and Development
2024
-
Current Report ESPI 17/2024
23/05/2024Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
2024
-
Current Report ESPI 16/2024
14/05/2024Preclinical and clinical data on RVU120 to be presented at the 2024 European Hematology Association Congress
2024
-
Current Report ESPI 15/2024
10/04/2024Posters on preclinical data on RVU120 and Synthetic Lethality Programs presented at the 2024 AACR Annual Meeting
2024
-
Current Report ESPI 14/2024
29/03/2024Conclusion of an agreement in the area of operational execution of RVU120 Phase II clinical trial in myelofibrosis
2024
-
Current Report ESPI 13/2024
27/03/2024Ryvu project recommended for funding by the Polish Agency for Enterprise Development
2024
-
Current Report ESPI 12K/2024
08/03/2024Correction of the current report No. 12/2024 of March 6, 2024 – correction of obvious typographical error
2024
-
Current Report ESPI 12/2024
06/03/2024Fulfillment of conditions for the disbursement of the Tranche A of financing from the European Investment Bank
2024
-
Current Report ESPI 11/2024
06/03/2024Preclinical data on RVU120 and Synthetic Lethality Programs to be presented at the 2024 AACR Annual Meeting
2024
-
Current Report ESPI 10/2024
14/02/2024Dosing of the first patient in the RIVER-52 Phase II Study of RVU 120 as a monotherapy for the treatment of patients with relapsed/refractory AML and HR-MDS
2024
-
Current Report ESPI 9/2024
09/02/2024Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
2024
-
Current Report ESPI 8/2024
07/02/2024Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
2024
-
Current Report ESPI 7/2024
05/02/2024Achievement of the second milestone under license agreement with Exelixis Inc.
2024
-
Current Report ESPI 6/2024
05/02/2024Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
2024
-
Current Report ESPI 5/2024
31/01/2024Dosing of the first patient in the RIVER-81 Phase II study of RVU120 in combination with venetoclax
2024
-
Current Report ESPI 4/2024
31/01/2024Registration of series K subscription warrants of the Company with the National Depository for Securities
2024
-
Current Report ESPI 3/2024
18/01/2024Publication dates for periodic reports in 2024
2024
-
Current Report ESPI 2/2024
18/01/2024Take-up of series K subscription warrants by the European Investment Bank
2024
-
Current Report ESPI 1/2024
03/01/2024Resignation of a member of the Company’s Supervisory Board from his position
2024
-
Current Report ESPI 49/2023
11/12/2023Presentation of preclinical data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting and additional clinical update
2023
-
Current Report ESPI 48/2023
11/12/2023Preclinical and clinical data on RVU120 presented at the 2023 American Society of Hematology (ASH) Annual Meeting
2023
-
Current Report ESPI 47/2023
07/12/2023Preclinical data on RVU120 to be presented at the San Antonio Breast Cancer Symposium 2023
2023
-
Current Report ESPI 46/2023
02/11/2023Clinical and preclinical data on RVU120 to be presented at the American Society of Hematology (ASH) Annual Meeting
2023
-
Current Report ESPI 45/2023
23/10/2023Ryvu presents updated clinical Phase I/II data of RVU120 in patients with relapsed/refractory metastatic or advanced solid tumors at the ESMO Congress 2023 together with the RVU120 Development Plan update
2023
-
Current Report ESPI 44/2023
20/10/2023Conclusion of a Clinical Trial Financial Support agreement for an investigator-initiated Phase II RVU120 study in Low-Risk Myelodysplastic Syndromes
2023
-
Current Report ESPI 43/2023
16/10/2023RVU120 poster to be presented at the European Society for Medical Oncology ESMO Congress 2023
2023
-
Current Report ESPI 42/2023
16/10/2023Posters on preclinical data on PRMT5 and Synthetic Lethality Platform presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
2023
-
Current Report ESPI 41/2023
04/10/2023Posters to be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
2023
-
Current Report ESPI 40/2023
14/09/2023Conclusion of an amendment to global License Agreement with Menarini Group
2023
-
Current Report ESPI 39/2023
04/08/2023Conclusion of two agreements in the area of operational execution of RVU120 Phase II clinical trials in hematology
2023
-
Current Report ESPI 38/2023
31/07/2023Conclusion of a financing agreement with the Medical Research Agency
2023
-
Current Report ESPI 37/2023
31/07/2023Conclusion of the agreement in the area of securing venetoclax supply chain for RVU120 Phase II clinical trial in combination therapy in hematology
2023
-
Current Report ESPI 36/2023
21/07/2023Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
2023
-
Current Report ESPI 35/2023
14/07/2023Conclusion of two agreements in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology
2023
-
Current Report ESPI 34/2023
06/07/2023Conclusion of two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials
2023
-
Current Report ESPI 33/2023
19/06/2023Registration of an amendment to the Articles of Association of the Company concerning conditional increase in the share capital of the Company
2023
-
Current Report ESPI 32/2023
14/06/2023Appointment of new Members of the Supervisory Board of Ryvu Therapeutics S.A.
2023
-
Current Report ESPI 31/2023
14/06/2023Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 14th, 2023
2023
-
Current Report ESPI 30/2023
14/06/2023Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
2023
-
Current Report ESPI 29/2023
13/06/2023Recommendation of Ryvu’s project for funding by the Medical Research Agency
2023
-
Current Report ESPI 28/2023
09/06/2023Publication of the updated clinical and preclinical data on RVU120
2023
-
Current Report ESPI 22K/2023
26/05/2023Correction of the current report on the convening of the Company’s Annual General Meeting
2023
-
Current Report ESPI 27/2023
25/05/2023Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
2023
-
Current Report ESPI 26/2023
25/05/2023Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
2023
-
Current Report ESPI 25/2023
25/05/2023Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
2023
-
Current Report ESPI 24/2023
25/05/2023Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
2023
-
Current Report ESPI 23/2023
23/05/2023Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
2023
-
Current Report ESPI 22/2023
18/05/2023Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
2023
-
Current Report ESPI 21/2023
16/05/2023Notification from PTE Allianz Polska S.A. of a change in its share in the total number of votes in the Company
2023
-
Current Report ESPI 20/2023
11/05/2023New clinical and preclinical data on RVU120 to be presented at the upcoming 2023 European Hematology Association Congress
2023
-
Current Report ESPI 19/2023
05/05/2023Conclusion of an agreement for the issuance of subscription warrants to the European Investment Bank
2023
-
Current Report ESPI 18/2023
20/04/2023Conclusion of the agreements concerning Phase II start-up services for RVU120 clinical studies in AML/HR-MDS
2023
-
Current Report ESPI 17/2023
12/04/2023Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
2023
-
Current Report ESPI 16/2023
06/04/2023Notice of termination regarding Option, License and Collaboration Agreement with Galapagos NV
2023
-
Current Report ESPI 15/2023
10/03/2023Change of publication date of the annual report for 2022
2023
-
Current Report ESPI 14/2023
02/03/2023Conclusion of an agreement concerning the operational execution of Phase II of Phase I/II clinical trial of RVU120 in Patients with Relapsed/Refractory Solid Tumors
2023
-
Current Report ESPI 13/2023
06/02/2023Receipt from a person discharging managerial responsibilities in the Company of a correction to the Article 19 MAR notification
2023
-
Current Report ESPI 12/2023
03/02/2023Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
2023
-
Current Report ESPI 11/2023
03/02/2023Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
2023
-
Current Report ESPI 10/2023
26/01/2023Achievement of the first milestone under licence agreement with Exelixis Inc.
2023
-
Current Report ESPI 07/2023
25/01/2023Announcement of the NDS on registration of series J shares with the NDS
2023
-
Current Report ESPI 09/2023
25/01/2023Publication dates for periodic reports in 2023
2023
-
Current Report ESPI 08/2023
25/01/2023Notification from TFI Allianz Polska S.A. of a change in its share in the total number of votes in the Company
2023
-
Current Report ESPI 06/2023
20/01/2023Admission and introduction of the series J shares of the Company to trading on the regulated market of the WSE
2023
-
Current Report ESPI 05/2023
20/01/2023Conditional registration of the series J shares of the Company with the National Depository for Securities
2023
-
Current Report ESPI 04/2023
19/01/2023Notification from a shareholder of a change in its share in the total number of votes in the Company
2023
-
Current Report ESPI 03/2023
18/01/2023Notification from a shareholder of a change in his share in the total number of votes in the Company
2023
-
Current Report ESPI 02/2023
18/01/2023Registration of amendment of the Company’s Articles of Association concerning share capital
2023
-
Current Report ESPI 01/2023
09/01/2023Notification from PTE Allianz Polska S.A. of a change in its share in the total number of votes in the Company
2023
-
Current Report ESPI 35/2022
22/12/2022Notification from a person discharging managerial responsibilities in the Company due to series J shares allotment – Article 19 of MAR
2022
-
Current Report ESPI 34/2022
22/12/2022Notification from a person closely related to a person discharging managerial responsibilities in the Company due to series J shares allotment – Article 19 of MAR
2022
-
Current Report ESPI 33/2022
22/12/2022Summary of the subscription of ordinary bearer series J shares
2022
-
Current Report ESPI 32/2022
22/12/2022Allotment of series J shares
2022
-
Current Report ESPI 31/2022
15/12/2022Determination of the final issue price of series J shares and the final number of series J shares that will be offered in the public offering
2022
-
Current Report ESPI 30/2022
11/12/2022Ryvu Therapeutics presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting
2022
-
Current Report ESPI 29/2022
07/12/2022Approval of the prospectus of the Company
2022
-
Current Report ESPI 28/2022
02/12/2022Decision to conduct public offering of J series shares in December 2022
2022
-
Current Report ESPI 27/2022
30/11/2022Disclosure of delayed confidential information regarding the start of negotiations and the non-binding determination of the key terms of a potential collaboration
2022
-
Current Report ESPI 26/2022
30/11/2022Execution of an exclusive Research Collaboration Option and Exclusive License Agreement and Equity Investment Agreement with BioNTech SE
2022
-
Current Report ESPI 25/2022
03/11/2022Clinical and Translational Data of RVU120 and SEL24 (MEN1703) to be presented at the 2022 American Society of Hematology (ASH) Annual Meeting
2022
-
Current Report ESPI 24/2022
26/10/2022Ryvu Therapeutics presents new clinical and preclinical data for RVU120 program at 34th AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
2022
-
Current Report ESPI 23/2022
12/10/2022Posters to be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
2022
-
Current Report ESPI 22/2022
05/10/2022Adoption by the Company’s Management Board of a resolution on issuance of shares within the framework of authorized capital and conclusion of lock-up agreements
2022
-
Current Report ESPI 21/2022
03/10/2022Registration of an amendment to the Company’s Articles of Association
2022
-
Current Report ESPI 20/2022
19/09/2022Shareholders controlling at least 5% of the votes at the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A. convened on September 19th, 2022
2022
-
Current Report ESPI 19/2022
19/09/2022Resolutions adopted by the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
2022
-
Current Report ESPI 18/2022
14/09/2022Self-correction to the draft resolution of the General Meeting of Ryvu Therapeutics S.A. convened for September 19, 2022
2022
-
Current Report ESPI 17/2022
19/08/2022Convening of the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
2022
-
Current Report ESPI 16/2022
19/08/2022Ryvu Therapeutics’ development plans for 2022-2024
2022
-
Current Report ESPI 15/2022
18/08/2022Change of the date of publication of the periodic report for the first half of 2022
2022
-
Current Report ESPI 14/2022
17/08/2022Conclusion of a financing agreement with the European Investment Bank
2022
-
Current Report ESPI 13/2022
26/07/2022Changes in Ryvu’s Management Board
2022
-
Current Report ESPI 12/2022
08/07/2022Information on a potential supply of shares in connection with the expiration of the lock-up period for shares under the Stock Grant Program
2022
-
Current Report ESPI 11/2022
07/07/2022Execution of an exclusive license agreement with Exelixis, Inc. to develop novel STING agonist-based targeted cancer therapies
2022
-
Current Report ESPI 10/2022
01/07/2022Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 30, 2022
2022
-
Current Report ESPI 09/2022
01/07/2022Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
2022
-
Current Report ESPI 08/2022
10/06/2022Publication of the updated phase 1b clinical and preclinical data for RVU120 and phase 1/2 SEL24 (MEN1703)
2022
-
Current Report ESPI 07/2022
03/06/2022Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
2022
-
Current Report ESPI 06/2022
12/05/2022New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Hybrid Congress 2022
2022
-
Current Report ESPI 05/2022
27/04/2022Ryvu Therapeutics to present recent RVU120 and SEL24 (MEN1703) data at ASCO 2022 Annual Meeting
2022
-
Current Report ESPI 04/2022
01/04/2022Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
2022
-
Current Report ESPI 03/2022
08/03/2022Ryvu Therapeutics to present recent data from oncology programs at AACR 2022 Annual Meeting
2022
-
Current Report ESPI 02/2022
19/01/2022Publication dates for periodic reports in 2022
2022
-
Current Report ESPI 01/2022
19/01/2022Delivery of a lawsuit for payment in connection with the construction of the Research and Development Center
2022
-
Current Report ESPI 40/2021
30/12/2021Ryvu Therapeutics to receive from Menarini Group a development milestone based on an amended global License Agreement
2021
-
Current Report ESPI 39/2021
20/12/2021Ryvu Therapeutics receives approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Spain
2021
-
Current Report ESPI 38/2021
17/12/2021Change order to the statement of work
2021
-
Current Report ESPI 37/2021
14/12/2021Galapagos NV exercises its exclusive option to license program with therapeutic potential in inflammatory diseases
2021
-
Current Report ESPI 36/2021
13/12/2021Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology (ASH) Annual Meeting and the 44th San Antonio Breast Cancer Symposium
2021
-
Current Report ESPI 35/2021
19/11/2021Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
2021
-
Current Report ESPI 34/2021
09/11/2021Ryvu Therapeutics to highlight HPK1 and STING Programs at the upcoming SITC Conference
2021
-
Current Report ESPI 33/2021
04/11/2021Ryvu’s partner Menarini Group receives FDA Orphan Drug Designation for SEL24 (MEN1703) for the Treatment of Acute Myeloid Leukemia
2021
-
Current Report ESPI 32/2021
04/11/2021Clinical and Translational Data from RVU120 and SEL24(MEN1703) programs to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition and the 44th Annual San Antonio Breast Cancer Symposium (SABCS)
2021
-
Current Report ESPI 31/2021
24/09/2021Filing a lawsuit against Mota-Engil Central Europe S.A. in connection with construction of the Research and Development Center
2021
-
Current Report ESPI 30/2021
25/08/2021First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors
2021
-
Current Report ESPI 29/2021
25/08/2021Resignation of the Member of the Management Board
2021
-
Current Report ESPI 28/2021
18/08/2021Notification from Aviva Otwarty Fundusz Emerytalny Aviva Santander on exceeding the threshold of 5% of the total number of votes in the Company
2021
-
Current Report ESPI 27/2021
13/08/2021Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
2021
-
Current Report ESPI 26/2021
21/07/2021Notification from person discharging managerial responsibilities in the Company – Article 19 of MAR
2021
-
Current Report ESPI 25/2021
14/07/2021FDA lifts partial clinical hold on RVU120 (SEL120) Phase Ib study in acute myeloid leukemia and myelodysplastic syndrome
2021
-
Current Report ESPI 24/2021
13/07/2021Notifications from persons discharging managerial responsibilities in the Company – Article 19 of MAR
2021
-
Current Report ESPI 23/2021
09/07/2021Information on the change in the shareholder structure due to execution of the Stock Grant Program in the Company – Art. 69 of the Act on Offerings
2021
-
Current Report ESPI 22K/2021
08/07/2021Correction of the current report No. 22/2021 of July 8, 2021
2021
-
Current Report ESPI 22/2021
08/07/2021Conclusion of the share donation agreement between the Company and President of the Management Board and main shareholder of the Company in execution of a non-diluting incentive program in the Company
2021
-
Current Report ESPI 21/2021
30/06/2021Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June, 29 2021
2021
-
Current Report ESPI 20/2021
30/06/2021Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
2021
-
Current Report ESPI 19/2021
11/06/2021Publication of clinical data for phase I RVU120 and phase I/II SEL24 (MEN1703)
2021
-
Current Report ESPI 18/2021
02/06/2021Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
2021
-
Current Report ESPI 18/2021
28/05/2021Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland
2021
-
Current Report ESPI 16/2021
20/05/2021Publication of abstract related to SEL24 (MEN1703) program at ASCO Annual Meeting 2021
2021
-
Current Report ESPI 15/2021
17/05/2021Shareholders controlling at least 5% of the vote at the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A. convened on May 17, 2021
2021
-
Current Report ESPI 14/2021
17/05/2021Resolutions adopted by the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
2021
-
Current Report ESPI 13/2021
13/05/2021Information concerning impact of non-diluting incentive program on Company’s financial statements
2021
-
Current Report ESPI 12/2021
12/05/2021New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Congress 2021
2021
-
Current Report ESPI 10/2021
20/04/2021Declaration of establishing a non-diluting incentive program in the Company for the years 2021-2024
2021
-
Current Report ESPI 09/2021
08/04/2021Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) by the FDA in Acute Myeloid Leukemia and Myelodysplastic Syndrome
2021
-
Current Report ESPI 08/2021
08/04/2021Notification from person discharging managerial responsibilities in the Company – Article 19 of MAR
2021
-
Current Report ESPI 07/2021
18/03/2021Conclusion of the grant agreement with the National Center for Research and Development
2021
-
Current Report ESPI 06/2021
11/03/2021Ryvu Therapeutics to present recent data from multiple oncology programs at AACR 2021 Virtual Annual Meeting
2021
-
Current Report ESPI 05/2021
08/03/2021Conclusion of an agreement concerning operational execution of Phase I clinical trial of RVU120 (SEL120) in solid tumors
2021
-
Current Report ESPI 04/2021
18/01/2021Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR
2021
-
Current Report ESPI 03/2021
13/01/2021Publication dates for periodic reports in 2021
2021
-
Current Report ESPI 02/2021
07/01/2021Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland
2021
-
Current Report ESPI 01/2021
04/01/2021The new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors submitted by Ryvu Therapeutics S.A.
2020
-
Current Report ESPI 43/2020
01/12/2020Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting
2020
-
Current Report ESPI 42/2020
23/11/2020Appointment of the new Management Board Member of Ryvu Therapeutics S.A.
2020
-
Current Report ESPI 40/2020
21/10/2020Revision of the Company’s research project pipeline
2020
-
Current Report ESPI 39/2020
14/10/2020Ryvu Therapeutics abstract concerning the STING program accepted for presentation at the SITC 2020
2020
-
Current Report ESPI 38/2020
12/10/2020Change of the registered office address of Ryvu Therapeutics S.A.
2020
-
Current Report ESPI 36/2020
16/09/2020First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703
2020
-
Current Report ESPI 34/2020
01/09/2020Appointment of Members of the Company’s Management and Supervisory Boards for a new term of office
2020
-
Current Report ESPI 33/2020
31/08/2020Shareholders controlling at least 5% of the vote at the General Meeting of Ryvu Therapeutics S.A. held on August 31, 2020
2020
-
Current Report ESPI 32/2020
31/08/2020Resolutions adopted by the Annual General Shareholders Meeting of Ryvu Therapeutics S.A.
2020
-
Current Report ESPI 31/2020
26/08/2020Introduction of the Series I Shares to trading on the main market operated by the WSE and designation of the last day of listing of Rights to Series I Shares
2020
-
Current Report ESPI 29/2020
19/08/2020Registration of share capital increase
2020
-
Current Report ESPI 28/2020
05/08/2020Completion of the subscription of Series I Shares
2020
-
Current Report ESPI 26/2020
30/07/2020Introduction of the Rights to Series I Shares to trading on the main market operated by the WSE
2020
-
Current Report ESPI 25/2020
27/07/2020Registration of the Rights to Series I Shares in the book-entry form by the National Depository for Securities
2020
-
Current Report ESPI 24/2020
22/07/2020Execution of subscription agreements and collection of cash contributions relating to series I shares in Ryvu Therapeutics S.A.
2020
-
Current Report ESPI 23/2020
15/07/2020Determination of the issue price of Series I shares issued by Ryvu Therapeutics S.A., the number of Series I shares to be offered for subscription by Ryvu Therapeutics S.A. and execution of the pricing supplement to the placement agreement
2020
-
Current Report ESPI 22/2020
13/07/2020Ryvu Therapeutics S.A. concludes a placement agreement and commences the book-building process for an offering by way of private subscription of new Series I ordinary bearer shares issued by Ryvu Therapeutics S.A.
2020
-
Current Report ESPI 21/2020
13/07/2020Shareholders controlling at least 5% of the vote at the General Meeting of Ryvu Therapeutics S.A. convened on July, 13 2020
2020
-
Current Report ESPI 20/2020
13/07/2020Resolutions adopted by the General Meeting of Ryvu Therapeutics S.A.
2020
-
Raport bieżący ESPI 18/2020
15/06/2020Ryvu Therapeutics Strategy for 2020-2022
2020